title: Effect of multiple intravenous pamidronate courses in Paget's disease of bone.
abstract: BACKGROUND
  Pamidronate is a bisphosphonate whose short-term biological efficacy in Paget's disease of bone was convincingly established many years ago. A less well studied area is the efficacy of pamidronate in slowing disease progression and in preventing and treating complications.
  
  
  METHODS
  We conducted an uncontrolled retrospective study of 79 Paget's disease patients given multiple intravenous pamidronate courses over a mean period of 45 +/- 19 months. The pamidronate dose per course was 180 mg, usually given over three days. The disease was severe and in some cases had proved refractory to other medications. Reasons for pamidronate therapy were pain or other subjective symptoms; established bone, joint, or nervous system complications; or prevention or these complications in patients with involvement of high-risk sites.
  
  
  RESULTS
  Bone and joint pain improved under therapy, and in 78% of cases the outcome in terms of complication treatment and/or prevention was favorable. An important finding was waning of the clinical and biological effects of pamidronate as the number of courses increased. Fourteen percent of patients developed resistance to pamidronate, which seemed more closely related to disease extension than to focal lesion activity.
  
  
  CONCLUSIONS
  These data suggest that a prompt return to normal of laboratory markers, most notably total alkaline phosphatase, should be sought, if needed by using higher doses than in our study.
authors.affiliation: Rheumatology and Bone Diseases Unit, Edouard Herriot Teaching Hospital, Lyon, France.
authors.forename: A
authors.initials: A
authors.lastname: Trombetti
authors.forename: M
authors.initials: M
authors.lastname: Arlot
authors.forename: J
authors.initials: J
authors.lastname: Thevenon
authors.forename: B
authors.initials: B
authors.lastname: Uebelhart
authors.forename: P J
authors.initials: PJ
authors.lastname: Meunier
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018488:Bone Demineralization, Pathologic / Q000000981:diagnostic imaging / Q000188:drug therapy; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007592:Joint Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D000077268:Pamidronate; D011859:Radiography; D012189:Retrospective Studies
chemical_list: D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D000077268:Pamidronate